Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
about
Targeted Approaches Applied to Uncommon Diseases: A Case of Salivary Duct Carcinoma Metastatic to the Brain Treated with the Multikinase Inhibitor Neratinib.Genomic alterations of ERBB receptors in cancer: clinical implications.Advances in the management of HER2-positive early breast cancer.Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs
P2860
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
description
2016 nî lūn-bûn
@nan
2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
@ast
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
@en
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
@nl
type
label
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
@ast
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
@en
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
@nl
prefLabel
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
@ast
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
@en
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
@nl
P2860
P356
P1476
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
@en
P2093
P2860
P304
P356
10.1177/1758834016656494
P407
P577
2016-09-01T00:00:00Z